NCT06097676View on ClinicalTrials.gov

An Abuse Potential Study of Orally Administered HORIZANT in Healthy, Non-dependent, Recreational Drug Users

PHASE4CompletedINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

September 28, 2021

Primary Completion Date

June 30, 2022

Study Completion Date

June 30, 2022

Conditions
Abuse Potential
Interventions
DRUG

Placebo

Placebo

DRUG

Alprazolam 2 mg

Oral dose of alprazolam 2 mg

DRUG

Gabapentin Enacarbil Immediate Release (GE-IR) 200 mg

Oral dose of GE-IR 200 mg

DRUG

Gabapentin Enacarbil Immediate Release (GE-IR) 450 mg

Oral dose of GE-IR 450 mg

DRUG

Gabapentin Enacarbil Immediate Release (GE-IR) 700 mg

Oral dose of GE-IR 700 mg

Trial Locations (1)

66212

Altasciences Clinical Kansas, Overland Park

Sponsors
All Listed Sponsors
lead

Arbor Pharmaceuticals, Inc.

INDUSTRY

NCT06097676 - An Abuse Potential Study of Orally Administered HORIZANT in Healthy, Non-dependent, Recreational Drug Users | Biotech Hunter | Biotech Hunter